The relationship between subclinical cardiovascular disease and lipocalin-2 levels in women with PCOS

Basit Öğe Kaydı
dc.contributor.authorGencer, Meryem
dc.contributor.authorGazi, Emine
dc.contributor.authorHacivelioglu, Servet
dc.contributor.authorBinnetoglu, Emine
dc.contributor.authorBarutcu, Ahmet
dc.contributor.authorTurkon, Hakan
dc.contributor.authorTemiz, Ahmet
dc.date.accessioned2025-01-27T20:31:48Z
dc.date.available2025-01-27T20:31:48Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: In this study we aimed to investigate the relationship between lipocalin-2 (LCN2) levels and cardiovascular risk in patients with polycystic ovary syndrome (PCOS). Study design: Fifty patients with PCOS and 44 healthy women as controls were enrolled in the study. Laboratory and echocardiographic examinations were performed between the second and fifth days of the menstrual cycle. Serum LCN2 levels were measured with an enzyme-linked immunosorbent assay (ELISA) method. Results: Serum LCN2 levels were significantly lower in PCOS patients (75.8 [51.4-131.2] ng/ml vs. 853 [56.7-138.5] ng/ml, p = 0.038). Carotid intima-media thickness (CIMT) was increased in patients with PCOS compared to controls (0.61 +/- 0.13 mm vs. 0.50 +/- 0.07 mm, p = 0.001). Aortic strain was lower in patients with PCOS. Aortic stiffness (beta index) was significantly increased and distensibility was decreased in PCOS patients compared to control subjects. Serum LCN2 levels and the presence of PCOS were associated with CIMT in Spearman correlation analysis (p = 0.05 and p < 0.001) in all participants. There was no statistically significant relationship between LCN2 levels and CIMT in patients with PCOS (p = 0.238). Conclusion: In the present study, we found that LCN2 levels were low in women with PCOS. Although our patients with PCOS had elevated cardiac risk, there was no correlation between LCN2 levels and early findings of atherosclerosis. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
dc.identifier.doi10.1016/j.ejogrb.2014.07.032
dc.identifier.endpage103
dc.identifier.issn0301-2115
dc.identifier.issn1872-7654
dc.identifier.pmid25145761
dc.identifier.scopus2-s2.0-84907979679
dc.identifier.scopusqualityQ2
dc.identifier.startpage99
dc.identifier.urihttps://doi.org/10.1016/j.ejogrb.2014.07.032
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23271
dc.identifier.volume181
dc.identifier.wosWOS:000343952000019
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectPCOS
dc.subjectLipocalin-2
dc.subjectAtherosclerosis
dc.subjectEchocardiography
dc.titleThe relationship between subclinical cardiovascular disease and lipocalin-2 levels in women with PCOS
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu